Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molibresib - GlaxoSmithKline

Drug Profile

Molibresib - GlaxoSmithKline

Alternative Names: GSK'762; GSK-525762; GSK525762A; GSK525762C; IBET762

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Amides; Antineoplastics; Benzodiazepines; Small molecules; Triazoles
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Carcinoma; Haematological malignancies; Prostate cancer; Solid tumours

Most Recent Events

  • 26 Aug 2021 Biomarkers information updated
  • 29 May 2020 Adverse events and therapeutic data from a phase I/II in Solid tumours presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 29 Apr 2020 Discontinued - Phase-I for Prostate cancer (Combination therapy, Hormone refractory, Late-stage disease, Metastatic disease) in United Kingdom, Spain, France, Canada, Australia, USA (PO) (GlaxoSmithKline pipeline, April 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top